Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402077 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
A Phase 2 study of Obesity and Overweight, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 258
- Enrollment target
- 16
- Study locations
NCT00402077: Completed Phase 2 study of Obesity and Overweight, sponsored by AstraZeneca.
NCT00402077 is a Phase 2 study of Obesity and Overweight that has completed, run by AstraZeneca. The registered enrollment target is 258 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00402077, a Phase 2 study of Obesity and Overweight, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 258 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
Conditions Studied
Interventions
- DRUG placebo
- DRUG pramlintide acetate
- DRUG sibutramine
- DRUG phentermine
Study Locations (16)
California
- Research Site - Chula Vista
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - Walnut Creek
Florida
- Research Site - Miami
- Research Site - Pembroke Pines
North Carolina
- Research Site - Raleigh
- Research Site - Statesville
Texas
- Research Site - Austin
- Research Site - San Antonio
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Phoenix
Kentucky
- Research Site - Louisville
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
What the finished NCT00402077 record still lists
NCT00402077 is an interventional study that assigns participants to a tested intervention. The registered 258 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (68% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which placebo is the first listed.
NCT00402077 lists 16 locations in 10 states (California, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00402077 about?
NCT00402077 is a clinical study titled "A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects". This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.
What is the current status of trial NCT00402077?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 258 participants. The study started on 2006-11. Estimated completion is 2007-08.
What conditions does trial NCT00402077 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT00402077?
The interventions under investigation include: placebo (DRUG), pramlintide acetate (DRUG), sibutramine (DRUG), phentermine (DRUG).
Who is sponsoring clinical trial NCT00402077?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00402077 being conducted?
This trial has 16 study locations across Alabama, Arizona, California, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00402077's enrollment target sits among peer trials
258 252nd of 1053 higher than 802 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03785288 · 258 participants · Phase 3
Vaginal Cuff Brachytherapy Fractionation Study
- NCT04643002 · 258 participants · Phase 1
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- NCT04924322 · 258 participants · Phase 2
Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies
- NCT05043012 · 258 participants · NA
Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia